Test Price
2,800 AED✅ Home Collection Available
ANOS1 Gene Kallmann Syndrome Type 1 Genetic Test | 2800 AED | DHA Licensed Laboratory
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing with full gene coverage across all 14 exons.
- Premium Logistics: VIP Mobile Phlebotomy and Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM across Dubai, Sharjah, and Abu Dhabi.
- Clinical Guidance: Mandatory pre-test genetic counseling session with pedigree documentation and telephonic post-test result interpretation by a board-certified genetic counselor.
- Insurance: Direct Billing Verification via WhatsApp at +971 54 548 8731 prior to sample collection.
Molecular genetic test for definitive diagnosis of congenital hypogonadotropic hypogonadism with anosmia, enabling personalized endocrine and fertility management.
Test Overview & Methodology
The ANOS1 Gene Kallmann Syndrome Type 1 NGS Test sequences the entire ANOS1 gene using next-generation sequencing to identify pathogenic variants responsible for congenital hypogonadotropic hypogonadism with anosmia. This UAE-based molecular diagnostic provides a definitive genetic confirmation, enabling endocrinologists and geneticists to tailor puberty induction and fertility preservation strategies. The assay achieves greater than 98 percent variant detection sensitivity, including deep intronic and splice-site variants that Sanger-based methods routinely miss.
| Feature | Our Test (Precision / Method / Speed) | Closest Alternative (Sanger Single-Exon) |
|---|---|---|
| Technology | NGS full gene sequencing (all 14 exons plus flanking regions) | Sanger sequencing of selected exons only |
| Diagnostic Yield | Greater than 98 percent variant detection including deep intronic and regulatory variants | Approximately 70 to 80 percent, misses rare pathogenic variants and splice-site alterations |
| Turnaround Time | 3 to 4 Weeks | 6 to 8 Weeks |
| Sample Requirement | Peripheral whole blood, extracted DNA, or buccal swab | Peripheral whole blood only |
| Genetic Counseling | Mandatory pre-test session with pedigree drawing and post-test disclosure | Not routinely offered |
Physician Insight & Safety Protocols
“Genetic confirmation of an ANOS1 variant provides families with a clear molecular diagnosis, but clinical management must integrate hormone profiling, MRI imaging, and longitudinal endocrine follow-up. This test offers diagnostic clarity—it does not replace specialist-led treatment decisions. Patients and caregivers should continue all prescribed therapies, including hormone replacement or growth hormone, until explicitly advised otherwise by their managing specialist.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Advisory: Pre-Test Preparation and Medication Safety
Important Clinical Guidance Before Sample Collection
- Maintain all current medications including hormone therapies, growth hormone, and gonadotropins unless your endocrinologist advises a temporary hold.
- Pre-test genetic counseling is mandatory and must be completed at least 48 hours prior to blood draw to allow informed consent and pedigree documentation.
- No fasting or dietary restrictions are required; the test can be performed at any time of day.
Exclusion Criteria and Emergency Red Flags
Situations Requiring Immediate Medical Attention
- This test is not for acute medical emergencies; do not delay care if experiencing severe headache, sudden vision loss, acute hearing changes, or signs of adrenal crisis such as vomiting, severe dehydration, or hypotension.
- Not a standalone fertility assessment; must be interpreted alongside hormonal evaluation including LH, FSH, testosterone, and inhibin B levels.
- Patients with active bleeding disorders, severe anemia, or those on anticoagulant therapy should consult their physician before venipuncture.
Patient FAQ & Clinical Guidance
1. What is the ANOS1 gene and why is this test ordered?
The ANOS1 gene provides instructions for producing anosmin-1, a protein essential for the normal migration of gonadotropin-releasing hormone neurons and olfactory nerve fibers. Pathogenic variants in ANOS1 cause Kallmann syndrome type 1, characterized by congenital hypogonadotropic hypogonadism and anosmia. This test is ordered when a patient presents with delayed or absent puberty, infertility, and an inability to smell, providing a definitive molecular diagnosis that guides hormone replacement therapy, fertility treatment, and family screening.
2. How is the sample collected and are there special preparations?
A simple peripheral blood draw or buccal swab is all that is required; no fasting, dietary changes, or medication adjustments are needed. Our DHA-licensed phlebotomist will visit your home or designated location anywhere in Dubai, Sharjah, or Abu Dhabi between 8 AM and 11 PM. A mandatory pre-test genetic counseling session must be completed prior to collection to document family history through a pedigree chart and obtain informed consent. Patients on anticoagulant therapy should confirm with their physician before venipuncture.
3. What is the turnaround time and how will I receive results?
Results are ready within 3 to 4 weeks from sample receipt at our laboratory. They are delivered securely via our encrypted patient portal accompanied by a telephonic result disclosure session with a genetic counselor. The comprehensive clinical report includes the variant description, pathogenicity classification according to ACMG/AMP guidelines, and management recommendations. Written copies are also transmitted through your preferred secure channel, and a follow-up consultation with the referring physician is encouraged for treatment planning.
UAE Regulatory & Data Privacy Adherence
All genetic data processing, storage, and transmission for the ANOS1 Gene Kallmann Syndrome Type 1 Genetic Test is conducted in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent procedures adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability. The laboratory holds ISO 9001:2015 certification (Certificate No. INT/EGQ/2509DA/3139) and operates under the regulatory oversight of the Dubai Health Authority. Genetic counseling and informed consent processes meet all mandatory DHA standards for predictive genetic testing.
Clinical & Logistical Metadata
| Test Name | ANOS1 Gene Kallmann Syndrome Type 1 Genetic Test (NGS Full Gene Sequencing) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3 to 4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood, Extracted DNA, or Buccal Swab |
| Methodology Used | Next-Generation Sequencing (NGS) — Full Gene Sequencing, all 14 exons plus flanking intronic regions |
| ICD-10-CM Code | E23.0 (Hypogonadotropic hypogonadism with anosmia) |
| LOINC Code | 81321-3 (ANOS1 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method) |
| DHA Facility License & Laboratory Address | DHA Facility License Number: 1143 — Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians